129 related articles for article (PubMed ID: 12176104)
1. A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors.
Lemaire W; O'Brien JA; Burno M; Chaudhary AG; Dean DC; Williams PD; Freidinger RM; Pettibone DJ; Williams DL
Eur J Pharmacol; 2002 Aug; 450(1):19-28. PubMed ID: 12176104
[TBL] [Abstract][Full Text] [Related]
2. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
[TBL] [Abstract][Full Text] [Related]
3. Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
Tsukada J; Tahara A; Tomura Y; Wada Ki ; Kusayama T; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
Br J Pharmacol; 2001 Jul; 133(5):746-54. PubMed ID: 11429400
[TBL] [Abstract][Full Text] [Related]
4. Effects of the non-peptide inhibitor OPC-21268 on oxytocin and vasopressin stimulation of rat and human myometrium.
Atke A; Vilhardt H; Hauzerova L; Barth T; Andersen LF
Eur J Pharmacol; 1995 Jul; 281(1):63-8. PubMed ID: 8566118
[TBL] [Abstract][Full Text] [Related]
5. Conformational aspects of differences in requirements for oxytocin and vasopressin receptors.
Oldziej S; Ciarkowski J; Liwo A; Shenderovich MD; Grzonka Z
J Recept Signal Transduct Res; 1995; 15(1-4):703-13. PubMed ID: 8903974
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Terrillon S; Cheng LL; Stoev S; Mouillac B; Barberis C; Manning M; Durroux T
J Med Chem; 2002 Jun; 45(12):2579-88. PubMed ID: 12036367
[TBL] [Abstract][Full Text] [Related]
7. Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.
Frantz MC; Rodrigo J; Boudier L; Durroux T; Mouillac B; Hibert M
J Med Chem; 2010 Feb; 53(4):1546-62. PubMed ID: 20104850
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
Cirillo R; Gillio Tos E; Schwarz MK; Quattropani A; Scheer A; Missotten M; Dorbais J; Nichols A; Borrelli F; Giachetti C; Golzio L; Marinelli P; Thomas RJ; Chevillard C; Laurent F; Portet K; Barberis C; Chollet A
J Pharmacol Exp Ther; 2003 Jul; 306(1):253-61. PubMed ID: 12660315
[TBL] [Abstract][Full Text] [Related]
9. Neuroanatomical distribution of oxytocin and vasopressin 1a receptors in the socially monogamous coppery titi monkey (Callicebus cupreus).
Freeman SM; Walum H; Inoue K; Smith AL; Goodman MM; Bales KL; Young LJ
Neuroscience; 2014 Jul; 273():12-23. PubMed ID: 24814726
[TBL] [Abstract][Full Text] [Related]
10. Small molecule ligands for oxytocin and vasopressin receptors.
Freidinger RM; Pettibone DJ
Med Res Rev; 1997 Jan; 17(1):1-16. PubMed ID: 8979247
[No Abstract] [Full Text] [Related]
11. 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.
Williams PD; Clineschmidt BV; Erb JM; Freidinger RM; Guidotti MT; Lis EV; Pawluczyk JM; Pettibone DJ; Reiss DR; Veber DF
J Med Chem; 1995 Nov; 38(23):4634-6. PubMed ID: 7473590
[No Abstract] [Full Text] [Related]
12. Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone.
Ogawa H; Yamamura Y; Miyamoto H; Kondo K; Yamashita H; Nakaya K; Chihara T; Mori T; Tominaga M; Yabuuchi Y
J Med Chem; 1993 Jul; 36(14):2011-7. PubMed ID: 8393113
[TBL] [Abstract][Full Text] [Related]
13. Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor.
Breton C; Chellil H; Kabbaj-Benmansour M; Carnazzi E; Seyer R; Phalipou S; Morin D; Durroux T; Zingg H; Barberis C; Mouillac B
J Biol Chem; 2001 Jul; 276(29):26931-41. PubMed ID: 11337500
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V(1A) receptor antagonist 4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl-(3,5-difluoro-phenyl) methanone (PF-00738245).
Russell R; Doyle R; Turner J; Attkins N; Ramsey S; Weibley L; Bateman L; Bictash M; Neal-Morgan S; Ivarsson M; Pullen N
Eur J Pharmacol; 2011 Nov; 670(2-3):347-55. PubMed ID: 21958878
[TBL] [Abstract][Full Text] [Related]
15. Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
Serradeil-Le Gal C; Raufaste D; Double-Cazanave E; Guillon G; Garcia C; Pascal M; Maffrand JP
Kidney Int; 2000 Oct; 58(4):1613-22. PubMed ID: 11012895
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells.
Tahara A; Tsukada J; Tomura Y; Wada Ki; Kusayama T; Ishii N; Yatsu T; Uchida W; Tanaka A
Br J Pharmacol; 2000 Jan; 129(1):131-9. PubMed ID: 10694212
[TBL] [Abstract][Full Text] [Related]
17. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
Gimpl G; Postina R; Fahrenholz F; Reinheimer T
Eur J Pharmacol; 2005 Mar; 510(1-2):9-16. PubMed ID: 15740719
[TBL] [Abstract][Full Text] [Related]
18. Non-peptide oxytocin agonists.
Pitt GR; Batt AR; Haigh RM; Penson AM; Robson PA; Rooker DP; Tartar AL; Trim JE; Yea CM; Roe MB
Bioorg Med Chem Lett; 2004 Sep; 14(17):4585-9. PubMed ID: 15357997
[TBL] [Abstract][Full Text] [Related]
19. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.
Serradeil-Le Gal C; Herbert JM; Delisee C; Schaeffer P; Raufaste D; Garcia C; Dol F; Marty E; Maffrand JP; Le Fur G
Am J Physiol; 1995 Jan; 268(1 Pt 2):H404-10. PubMed ID: 7840290
[TBL] [Abstract][Full Text] [Related]
20. Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
Griffante C; Green A; Curcuruto O; Haslam CP; Dickinson BA; Arban R
Br J Pharmacol; 2005 Nov; 146(5):744-51. PubMed ID: 16158071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
